Aligos Therapeutics, Inc.

NASDAQ:ALGS

39.34 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q22018 Q1
Revenue 1.2691.0610.9862.6813.2396.8862.7233.5374.1063.6932.5710.3671.5371.5450.9102.02600000000
Cost of Revenue 00.610.6740.7750.6810.7690.8440.8970.9060.8890.98328.59828.13224.55422.86928.08117.33217.17617.302000000
Gross Profit 1.2690.4510.3121.9062.5586.1171.8792.643.22.8041.588-28.231-26.595-23.009-21.959-28.081-15.306-17.176-17.302000000
Gross Profit Ratio 10.4250.3160.7110.790.8880.690.7460.7790.7590.618-76.924-17.303-14.893-24.1310-7.55500000000
Reseach & Development Expenses 16.77421.09916.36622.25715.86716.78118.13519.117.79116.5131.67628.59828.13224.55422.86928.08117.33217.17617.30214.97311.7298.6688.6682.6142.614
General & Administrative Expenses 4.6266.3766.6666.4216.4439.2468.5067.1195.2637.5766.4529.7176.4736.5565.7816.2054.2254.0953.4193.4632.7751.8841.8840.8010.801
Selling & Marketing Expenses 0-0.610-0.775000000000000000000000
SG&A 4.6265.7666.6665.6466.4439.2468.5067.1195.2637.5766.4529.7176.4736.5565.7816.2054.2254.0953.4193.4632.7751.8841.8840.8010.801
Other Expenses 031.345-13.373-0.460.0540.1520.2540-0.1820.304-0.09100.05-0.2980.0061.07-11.9740.0410.2240.0830.10800-6.831-6.831
Operating Expenses 21.426.86523.03227.90322.3126.02726.64126.21923.05424.08638.12838.31534.60531.1128.6534.28621.55721.27120.72118.43614.50410.49710.497-3.415-3.415
Operating Income -20.131-26.414-22.046-25.997-19.071-19.141-21.914-22.682-18.948-20.393-35.557-37.948-33.068-29.565-27.74-34.286-21.557-21.271-20.721-18.436-14.504-10.552-10.552-3.415-3.415
Operating Income Ratio -15.864-24.895-22.359-9.697-5.888-2.78-8.048-6.413-4.615-5.522-13.83-103.401-21.515-19.136-30.4840-10.6400000000
Total Other Income Expenses Net 0.96331.664-12.793-1.9251.0591.1071.0020.8450.2840.516-0.0050.1760.07-0.2250.1110.085-11.740.4150.6920.3370.4530.5370.537-0.068-0.068
Income Before Tax -19.1685.25-34.839-27.922-18.012-18.034-22.916-21.837-18.664-19.877-35.562-37.772-32.998-29.79-27.629-34.201-33.297-20.856-20.029-18.099-14.051-10.015-10.015-3.483-3.483
Income Before Tax Ratio -15.1054.948-35.334-10.415-5.561-2.619-8.416-6.174-4.546-5.382-13.832-102.921-21.469-19.282-30.3620-16.43500000000
Income Tax Expense 0.0910.189-0.024-0.030.0290.7570.0390.049-0.0430.0470.053-0.0580.1260.0280.0450.219-0.234-0.059-0.4680.085-0.34500-0.068-0.068
Net Income -19.2595.061-34.863-27.892-18.041-18.791-22.955-21.886-18.621-19.924-35.615-37.714-33.124-29.818-27.674-34.42-33.297-20.797-20.029-18.184-14.051-10.015-10.015-3.483-3.483
Net Income Ratio -15.1774.77-35.358-10.404-5.57-2.729-8.43-6.188-4.535-5.395-13.853-102.763-21.551-19.3-30.4110-16.43500000000
EPS -3.070.81-5.58-1.12-0.41-0.43-0.53-0.51-0.44-0.47-0.84-0.89-0.78-0.79-0.74-1.09-0.9-0.95-0.91-0.83-0.64-0.46-0.46-0.16-0.16
EPS Diluted -3.070.81-5.58-1.12-0.41-0.43-0.53-0.51-0.44-0.47-0.84-0.89-0.78-0.79-0.74-1.09-0.9-0.95-0.91-0.83-0.64-0.46-0.46-0.16-0.16
EBITDA -19.464-26.414-21.372-27.147-18.39-18.372-23.074-22.16-17.758-19.504-34.579-37.948-32.031-28.865-26.756-33.318-20.842-20.312-20.261-17.792-13.878-10.311-10.311-3.161-3.161
EBITDA Ratio -15.338-24.32-22.359-9.408-5.678-2.668-8.784-6.413-4.394-5.281-13.448-103.401-20.885-18.537-29.5240-10.20300000000